Virax Biolabs Group (NASDAQ:VRAX) Raised to “Hold” at Zacks Research

Virax Biolabs Group (NASDAQ:VRAX) was upgraded by research analysts at Zacks Research to a “hold” rating in a report released on Tuesday,Zacks.com reports.

A number of other analysts have also commented on VRAX. HC Wainwright reiterated a “buy” rating and issued a $1.00 price objective (down from $3.00) on shares of Virax Biolabs Group in a research report on Friday, January 9th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Virax Biolabs Group in a research report on Friday, January 9th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Virax Biolabs Group currently has a consensus rating of “Hold” and a consensus target price of $1.00.

Virax Biolabs Group Stock Performance

VRAX stock opened at $0.33 on Tuesday. The company has a 50 day moving average price of $0.42 and a 200 day moving average price of $0.62. Virax Biolabs Group has a fifty-two week low of $0.30 and a fifty-two week high of $2.46.

Virax Biolabs Group (NASDAQ:VRAX) last announced its quarterly earnings data on Tuesday, December 2nd. The company reported ($0.27) EPS for the quarter. The business had revenue of $0.00 million during the quarter.

About Virax Biolabs Group

Virax Biolabs Group (NASDAQ: VRAX) is a clinical-stage biotechnology company focused on the research, development and manufacturing of next-generation vaccines targeting respiratory and other infectious diseases. Headquartered in Australia, the company leverages advanced viral vector platforms to create novel immunization solutions designed to induce both systemic and mucosal immunity. Virax Biolabs is publicly traded on the NASDAQ exchange under the symbol VRAX.

At the core of Virax Biolabs’ pipeline is a proprietary adenoviral vector platform, licensed exclusively from a leading academic institution, which serves as the backbone for intranasal and injectable vaccine candidates.